To include your compound in the COVID-19 Resource Center, submit it here.

Limited use of ESAs

Limited use of ESAs

Limited use of ESAs
CMS has proposed limited coverage of ESAs for anemia in cancers where the presence of erythropoietin receptor on either

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE